MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital Clínico Universitario Lozano Blesa](/img/noimage_org.png)
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (12)
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
2020
-
Breakthrough cancer pain: review and calls to action to improve its management
Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1216-1226
2019
2018
-
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686
2017
-
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Tumor Biology, Vol. 39, Núm. 6
-
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
British Journal of Cancer, Vol. 117, Núm. 12, pp. 1777-1786
2015
2014
-
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248
2013
-
Phase ii study of irinotecan in combination with capecitabine on a 3-weekly schedule as first-line chemotherapy for patients with metastatic or locally advanced colorectal cancer
Journal of Analytical Oncology, Vol. 2, Núm. 3, pp. 151-159
2010
-
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer
Chemotherapy, Vol. 56, Núm. 2, pp. 142-146
2005
-
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
European Journal of Cancer, Vol. 41, Núm. 15, pp. 2241-2249
2003
-
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer
Clinical Colorectal Cancer, Vol. 3, Núm. 2, pp. 108-112